A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients with Advanced Stage Epithelial Ovarian Cancer

• Histologically confirmed surgical diagnosis of stage IIIC or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; patients with stage III cancer must have had peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis; NOTE: Histologic confirmation of the primary tumor is required; eligible histologies include serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, or mixed carcinoma

• Completion of cytoreductive surgery and has completed one (and only one) course of platinum-based chemotherapy (5-9 cycles) \>= 4 but =\< 20 weeks prior to registration; NOTE: cytoreductive surgery may have been prior to or after the first cycle of chemotherapy but must include hysterectomy and bilateral salpingo-oophorectomy, if the uterus and/or ovaries had not previously been removed; NOTE: patients may have had more than one chemotherapy regimen (ex: paclitaxel/carboplatin switched to docetaxel/carboplatin due to allergy; weekly treatment switched to every 3 week treatment due to intolerance), but may not have received a separate course of treatment for recurrent ovarian cancer (OC); NOTE: patients may receive both neoadjuvant and adjuvant chemotherapy provided both regimens are platinum-based and total 9 or fewer chemotherapy cycles

• No evidence of disease at the time of registration, including no clinical concern for disease recurrence based on each of the following:

‣ No evidence of disease by history and physical exam

⁃ Cancer antigen (CA)125 within normal limits

⁃ Computed tomography (CT) abdomen/pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy =\< 28 days before entering study

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L

• Platelet count \>= 75 x 10\^9/L

• Hemoglobin \>= 8.5 g/dL

• Lymphocytes \>= 0.3 x 10\^9/L

• Total bilirubin =\< 2 x upper limit of normal (ULN), unless patient has a documented history of Gilbert's disease, then direct bilirubin =\< 1.0 mg/dL

• Aspartate transaminase (AST) =\< 3 x ULN

• Creatinine =\< 2.0 mg/dL

• Monocytes \>= 0.25 x 10\^9/L

• Able to provide informed written consent

• Expected survival \> 6 months

• Willingness to return to Mayo Clinic Rochester for follow-up appointments

• Willingness to provide blood samples for immune assessment and other tests

• Willingness to undergo a tetanus vaccination